Call Us: 1.800.873.5297

By

Xarelto® Blood Thinning Medication Causes Uncontrolled Bleeding, New Lawsuit Alleges

PillsAccording to a recent lawsuit filed in the Philadelphia County Court of Common Pleas (Stuntebeck v. Johnson & Johnson, et al.), the anticoagulant drug, Xarelto® (rivaroxaban), is alleged to cause serious and uncontrolled internal bleeding that might be irreversible, that could result in life-threatening injuries and even death.

The anti-clotting medication Xarelto®, which is marketed by Johnson & Johnson in the U.S. and by Bayer outside the U.S., was approved by the Food and Drug Administration (FDA) in July 2011 for use in patients who recently underwent hip or knee replacement surgery to reduce the risk of blood clots. In November 2011, the FDA expanded the use of Xarelto® for patients with atrial fibrillation (AF) to reduce the risk of stroke. Then in 2012, the FDA expanded the use of Xarelto® for the general treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE). According to recent reports, Bayer has been trying to get Xarelto® approved for use in acute coronary syndrome (ACS) patients, but the FDA in February turned them down for the third time.

A lawsuit involving another blood thinning medication, Pradaxa®, recently resulted in a $650 Million settlement to resolve approximately 4,000 Pradaxa® claims. Like Pradaxa®, Xarelto® has no known antidote for uncontrolled bleeding and does not require regular monitoring of blood levels.

The current market for blood thinning medications, including Xarelto®, is estimated to be worth $10 billion. Last year, Xarelto® sales reached $1.3 Billion and Bayer’s Chief Executive, Marijn Dekkers, expects that sales will reach around 3.5 Billion Euros annually.

“We will fight for the rights of individuals who allege to have experienced serious and life-threatening injuries after using Xarelto®,” says Roger Denton of Schlichter, Bogard & Denton, LLP. The attorneys at Schlichter, Bogard & Denton, LLP are offering free and confidential case reviews to those who allege to have been injured after using Xarelto®.

 

About Schlichter, Bogard & Denton, LLP
Schlichter, Bogard & Denton, LLP is a unique law firm that has held numerous leadership positions in national litigations involving dangerous pharmaceutical medications and unsafe medical devices, including but not limited to: In re: Pradaxa® (Dabigatran Etexilate) Products Liability (MDL 2385), In re: Yasmin® and Yaz® (Drospirenone) Marketing and Sales Practices and Products Liability Litigation (MDL 2100), In re: NuvaRing® Products Liability Litigation (MDL 1964), In re: Gadolinium-Based Contrast Products Liability Litigation (MDL 1909), and In re: Ortho Evra® Products Liability Litigation (MDL 1742).

The Pharmaceuticals and Medical Litigation Department at Schlichter, Bogard & Denton aggressively represent clients who allege to have suffered injuries as a result of dangerous pharmaceutical medications and unsafe medical devices. The attorneys at Schlichter, Bogard & Denton, LLP who represent such victims include Roger Denton, Kristine Kraft, Beth Wilkins Flieger, Ashley Brittain Landers, and Tara Rocque. With hard work, creative thinking, and strong trial skills, we have earned an outstanding nationwide reputation by representing thousands of individuals who have suffered serious and life-threatening injuries, or even death.

If you or a loved one has suffered serious injuries after using Xarelto®, please contact the attorneys at Schlichter, Bogard & Denton, LLP toll-free at 1-800-873-5297 for your confidential and free consultation.

Schlichter, Bogard & Denton, LLP also welcomes the opportunity to work with other attorneys on these types of cases. Schlichter, Bogard & Denton, LLP is available to either handle these cases or work as co-counsel, so other attorneys with these types of cases are invited to contact an attorney at the firm to explore this opportunity.

The choice of a lawyer is an important decision and should not be based solely on advertisements. The cases discussed do not predict outcomes in future cases. Past results afford no guarantee of future results and every case is different and must be judged on its own merits.

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.